Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Thomas

Showing results (101-110 of 262) with videos related to

Pageof 27
Sort By:
Leukemia & Lymphoma|June 3, 2014
Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemiaAdriana Plesa, Mohamed Elhamri, Gilles Clapisson, et al.
Leukemia & Lymphoma|July 17, 2014
Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblingsMauricette Michallet, Mohamad Sobh, Caroline Serrier, et al.
BMC Cancer|July 12, 2008
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialJorge Sierra, Jeffrey Szer, Jeannine Kassis, et al.
Cancer|February 10, 2010
Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF studyXavier Thomas, Emmanuel Raffoux, Aline Renneville, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2007
Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposureThomas Bénet, Marie-Christine Nicolle, Anne Thiebaut, et al.
Leukemia & Lymphoma|June 22, 2013
Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemiaCaroline Le Jeune, Sarah Bertoli, Mohamed Elhamri, et al.
Journal of Blood Medicine|February 14, 2015
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemiaChristopher Arthur, Jaroslav Cermak, Jacques Delaunay, et al.
Annals of Hematology|March 23, 2005
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trialXavier Thomas, Mohamed Elhamri, Youcef Chelghoum, et al.
Annals of Hematology|December 25, 2016
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?Etienne Paubelle, Sophie Ducastelle-Leprêtre, Hélène Labussière-Wallet, et al.
Haematologica|April 5, 2011
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaRaphael Itzykson, Claude Gardin, Cécile Pautas, et al.
Pageof 27

Showing results (101-110 of 262) with videos related to

Sort By:
Pageof 27
Leukemia & Lymphoma|June 3, 2014
Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemiaAdriana Plesa, Mohamed Elhamri, Gilles Clapisson, et al.
Leukemia & Lymphoma|July 17, 2014
Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblingsMauricette Michallet, Mohamad Sobh, Caroline Serrier, et al.
BMC Cancer|July 12, 2008
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialJorge Sierra, Jeffrey Szer, Jeannine Kassis, et al.
Cancer|February 10, 2010
Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF studyXavier Thomas, Emmanuel Raffoux, Aline Renneville, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2007
Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposureThomas Bénet, Marie-Christine Nicolle, Anne Thiebaut, et al.
Leukemia & Lymphoma|June 22, 2013
Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemiaCaroline Le Jeune, Sarah Bertoli, Mohamed Elhamri, et al.
Journal of Blood Medicine|February 14, 2015
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemiaChristopher Arthur, Jaroslav Cermak, Jacques Delaunay, et al.
Annals of Hematology|March 23, 2005
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trialXavier Thomas, Mohamed Elhamri, Youcef Chelghoum, et al.
Annals of Hematology|December 25, 2016
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?Etienne Paubelle, Sophie Ducastelle-Leprêtre, Hélène Labussière-Wallet, et al.
Haematologica|April 5, 2011
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaRaphael Itzykson, Claude Gardin, Cécile Pautas, et al.
Pageof 27